Menu +

Tag: trial

New Clinical Trial for a COVID-19 Vaccine Authorised in Germany

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines has authorised another Phase-1 clinical trial of a vaccine against COVID-19 in Germany. The new vaccine candidate is a so-called vector vaccine. Trials on vaccine candidates in humans are a significant step in the direction of authorising safe and efficacious vaccines against COVID-19. This new vaccine is […]

Paul-Ehrlich-Institut – Another Clinical Trial of a COVID-19 Vaccine authorised in Germany

Spike-Protein on SARS-CoV-2 (Source: S.Myshkovsky/photodisc/Gettyimages)

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, has authorised another clinical trial of a vaccine against COVID-19 in Germany. The intensive preliminary scientific advice of the medicines developer CureVac, and the prioritisation of the regulatory activities at the Paul-Ehrlich-Institut for vaccines and biomedicines against COVID-19 have made it possible to complete the authorisation procedure […]

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia

Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra®/RoActemra® (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer. Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate […]

Paul-Ehrlich Institut : First Clinical Trial of a COVID-19 Vaccine Authorised in Germany

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, has authorised the first clinical trial of a vaccine against COVID-19 in Germany. Spike-Protein SARS-CoV-2 (Source: Viaframe/Corbis/GettyImages) The authorisation of this trial is the result of a careful assessment of the potential risk/benefit profile of the vaccine candidate. Based on extensive scientific advice to the medicine developer, […]